Back to YC Companies
Arpeggio Bio
Summer 2019
Active
Arpeggio Bio develops drugs targeting transcription factors using AI…
20 people View on YC
Arpeggio Bio at a glance
- Y Combinator batch
- Summer 2019
- Status
- Active
- Industry
- Healthcare
- Team size
- 20 people
- Location
- Not recorded
- Website
- Not recorded
Every field above comes from the Y Combinator company record. Nothing is estimated.
About Arpeggio Bio
Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
Tags:
Biotech
Genomics
Drug discovery